Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals Reports Q2 Earnings Beat, Investigates Retinal Vasculitis Events

Apellis Pharmaceuticals beats Q2 earnings estimates with strong sales of SYFOVRE, but faces investigation into retinal vasculitis events

Zenger · Aug 1, 2023

1 Medical Stock You Shouldn't Touch With a 10-Foot Pole

1 Medical Stock You Shouldn't Touch With a 10-Foot Pole

Apellis Pharmaceuticals’ (APLS) stock has jumped more than 25% year-to-date based on FDA approval for treating geographic atrophy. Despite the breakthrough, the company’s ability to scale up production remains a concern. Moreover, its closest competitor is also close to getting approval. Given its poor financials, stretched valuation, and weak profitability,…

StockNews.com · Mar 6, 2023

Why Apellis Pharmaceuticals Stock Is Falling After Hours

Why Apellis Pharmaceuticals Stock Is Falling After Hours

Apellis Pharmaceuticals Inc (NASDAQ: APLS) shares are trading lower in Wednesday's after-hours session after the company announced a proposed public offering of $300 million of its common stock.

Benzinga · Mar 23, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Apellis' Pegcetacoplan Showed Continuous, Meaningful Effects At Month 18 In Geographic Atrophy Studies

Apellis Pharmaceuticals Inc (NASDAQ:APLS) announced longer-term data from the Phase 3 DERBY and OAKS studies, which showed that intravitreal pegcetacoplan continued to reduce geographic atrophy (GA) lesion growth. These data will be included in the U.S. marketing application that the Company plans to submit in Q2 of 2022. In the OAKS study,…

Benzinga · Mar 16, 2022

Here's Why Apellis Pharmaceuticals Shares Are Rising

Apellis Pharmaceuticals Inc (NASDAQ: APLS) shares are trading higher by 8.6% at $43.49 after the company announced Pegcetacoplan showed continuous and clinically meaningful effects at month 18 in Phase 3 Derby and Oaks studies for geographic atrophy.

Benzinga · Mar 16, 2022

1

Coverage From

People

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Apellis Pharmaceuticals

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

423,747 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play